Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy

New England Journal of Medicine

Volumn 375, Issue 19, 2016, Pages 1845-1855

  Eggermont, A M M ^a   Chiarion sileni, V ^f   Grob, J J ^b   Dummer, R ^k   Wolchok, J D ^l   Schmidt, H ^m   Hamid, O ^o   Robert, C ^a   Ascierto, P A ^g   Richards, J M ^p   Lebbe C ^c   Ferraresi, V ^h   Smylie, M ^q   Weber, J S ^r   Maio, M ⁱ   Bastholt, L ⁿ   Mortier, L ^d   Thomas, L ^e   Tahir, S ^s   Hauschild, A ^t   Hassel, J C ^u   Hodi, F S ^v   Taitt, C ^w   De Pril, V ^w   De Schaetzen, G ^x   Suciu, S ^x   Testori, A ^j   more..

^a AIX MARSEILLE UNIVERSITY   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Lille Hospital   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h Istituti Fisioterapici Ospitalieri Rome   (Italy)

ⁱ UNIVERSITY HOSPITAL OF SIENA   (Italy)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l Memorial Sloan Kettering Cancer Center   (Denmark)

^m AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁿ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^o Angeles Clinic and Research Institute   (United States)

^p Oncology Specialists   (United States)

^q CROSS CANCER INSTITUTE   (Canada)

^r H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^s BROOMFIELD HOSPITAL   (United Kingdom)

^t UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^u UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^v DANA FARBER CANCER INSTITUTE   (United States)

^w BRISTOL MYERS SQUIBB   (United States)

^x EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; BIOLOGICAL RESPONSE MODIFIER; IPILIMUMAB; PLACEBO; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANAPHYLAXIS; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLITIS; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISTANT METASTASIS FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOPHYSITIS; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; RECURRENCE FREE SURVIVAL; SIDE EFFECT; UVEITIS; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; GASTROINTESTINAL DISEASE; IMMUNOLOGY; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SKIN NEOPLASMS; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84994874924     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1611299     Document Type: Article

References (23)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
3. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-64.
4. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-Term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33: 1889- 94.
5. Eggermont AMM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383: 816-27.
6. Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
7. Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2, 313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28: 2452-9.
8. van Akkooi ACJ, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008; 248: 949-55.
9. van der Ploeg APT, van Akkooi ACJ, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 2011; 29: 2206- 14.
10. van der Ploeg APT, van Akkooi ACJ, Haydu LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel nodepositive melanoma patients. Eur J Cancer 2014; 50: 111-20.
11. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of highrisk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522-30.
12. Coens C, Suciu S, Vanna Chiarion-Sileni V, et al. Phase III trial (EORTC 18071/CA184-029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: health related quality of life (HRQoL) results. Lancet Oncol (in press).
13. Suciu S, Ives N, Eggermont AM, et al. Predictive importance of ulceration on the efficacy of adjuvant interferon-A (IFN): An individual patient data (IPD) meta-Analysis of 15 randomized trials in more than 7, 500 melanoma patients (pts). J Clin Oncol 2014; 32: Suppl:5. abstract.
14. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-Alpha for high-risk melanoma provide a worthwhile benefit? A metaanalysis of the randomised trials. Cancer Treat Rev 2003; 29: 241-52.
15. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-Analysis. J Natl Cancer Inst 2010; 102: 493-501.
16. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-15.
17. Eggermont AM, Suciu S, Rutkowski P, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-Alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer 2016; 55: 111-21.
18. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline - update 2016. Eur J Cancer 2016; 63: 201-17.
19. Eggermont AMM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366: 1189-96.
20. Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-26.
21. Eggermont AM, Suciu S, Testori A, et al. Long-Term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012; 30: 3810-8.
22. Eggermont AMM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48: 218-25.
23. Eggermont AM, Spatz A, Lazar V, Robert C. Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol 2012; 24: 137-40.